Relay adds executives to its chemistry, R&D teams as it transitions to the development stage

laboratory
Relay plans to expand its protein motion platform to an “expanding array of therapeutic targets” as it transitions to the development stage. (Pixabay)

Former Fierce 15 winner Relay Therapeutics has brought on Verastem’s Mahesh Padval, Ph.D., and Eli Lilly’s Mary Mader, Ph.D., to boost its drug discovery and development operations in oncology as it begins to transition to an R&D-stage biotech.

Padval was appointed as Relay’s senior VP of pharmaceutical drug development, while Mader was named VP of chemistry.

At Verastem, Padval served as VP of pharmaceutical sciences and product development, helping to oversee preclinical development, CMC and clinical pharmacology activities—including for the September approval and launch of Copiktra in third-line chronic lymphocytic leukemia, small lymphocytic leukemia and follicular lymphoma, which is expected to reach between $500 million and $850 million in peak sales.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: FierceBiotech's 2017 Fierce 15 | Relay Therapeutics

Prior to Verastem, Padval was VP of preclinical development and formulations at Zalicus, and he also held roles at Charles River Discovery and Development Services and Genzyme Transgenics.

Mader previously served as a senior research advisory and a research fellow at Eli Lilly, where she worked on the discovery and development of multiple clinical candidates. Before that, she was a visiting research scientist at the Bayer Research Center and an associate professor at Grinnell College in Iowa.

RELATED: New investors, including GV, boost Relay in $63M round

Relay’s pipeline focuses on studying the movement of proteins within cells in real-time. Its discovery engine examines the full mobility of a protein and the ways that motion can regulate function.

The company’s head of R&D, Don Bergstrom, M.D., Ph.D., said the company plans to expand its protein motion platform to an “expanding array of therapeutic targets” as it transitions to the development stage.